FAVRILLE'S FAVID STUDY DATA PUBLISHED

A A

Favrille has announced that data from its initial Phase II clinical trial evaluating FavId as a single therapeutic agent in previously treated and relapsed patients with indolent B-cell non-Hodgkin's lymphoma (NHL) have been published in the Journal of Clinical Oncology.

The article, entitled "Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses," concludes that FavId as a single agent is active and well tolerated in previously treated and relapsed patients with indolent B-cell NHL. Results from this multi-center trial demonstrated a median time to disease progression for the 31 evaluable patients in the trial of 13.5 months. The most common adverse events reported were mild-to-moderate injection site reactions.